Literature DB >> 8471657

Analysis of lymphocyte subsets in patients with aplastic anemia before and during immunosuppressive therapy.

U Mentzel1, H Vogt, R Rossol, R G Geissler, A Maurer, A Ganser, W E Trommer, D Hoelzer.   

Abstract

To define the contribution of T-lymphocyte subsets in the development of aplastic anemia (AA), T-cell subpopulations including alpha beta T cells, gamma delta T cells, and delta TCS1-positive gamma delta T cells, were analyzed by cytophotometry in the peripheral blood (PB) and bone marrow (BM) of patients with AA before and after 6 weeks of therapy with anti-lymphocyte globulin (ALG), methylprednisolone, and cyclosporin A (CSA). In nine patients with AA a significant decrease of PB- and BM-derived T cells was observed after 6 weeks of therapy as compared with normal controls. At diagnosis, the CD4/CD8 ratio in PB and BM of the patients did not differ from the ratio in the control population; however, a reversed ratio (< 1) was present in PB as well as in BM after weeks of therapy. Interestingly, lymphocytes expressing the gamma delta T-cell receptor (TCR tau delta) were significantly decreased both before (PB 1.2 +/- 0.1%; BM 0.8 +/- 0.1%) and after 6 weeks of therapy (PB 0.7 +/- 0.1%; BM 0.7 +/- 0.1%) as compared with healthy controls (PB 2.4 +/- 0.2%; BM 2.3 +/- 0.2%). However, the proportion of the gamma delta-T-cell subpopulation expressing the delta TCS1 phenotype was markedly increased before (PB 42 +/- 3.5%; BM 31 +/- 3%) and especially after 42 days of therapy (PB 77 +/- 12%; BM 45 +/- 2%) as compared with that in normal subjects (PB 19 +/- 2%; BM 9.7 +/- 0.8%). At present, follow-up is under evaluation to correlate these findings with hematological response. The pathophysiological significance of the observed alterations within the T-cell subsets and especially the gamma delta T-cell populations will require further functional analyses, in particular since delta TCS1-positive gamma delta T cells exhibit autoimmunological capacity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8471657     DOI: 10.1007/bf01697621

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  8 in total

Review 1.  TCR gamma delta cells--minor redundant T cell subset or specialized immune system component?

Authors:  J A Bluestone; L A Matis
Journal:  J Immunol       Date:  1989-03-15       Impact factor: 5.422

Review 2.  Pathophysiology of aplastic anaemia.

Authors:  C Nissen
Journal:  Acta Haematol       Date:  1991       Impact factor: 2.195

3.  Lymphocyte phenotype and lymphokines following anti-thymocyte globulin therapy in patients with aplastic anaemia.

Authors:  L Platanias; P Gascon; L Bielory; P Griffith; A Nienhuis; N Young
Journal:  Br J Haematol       Date:  1987-08       Impact factor: 6.998

4.  Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group.

Authors:  N Frickhofen; J P Kaltwasser; H Schrezenmeier; A Raghavachar; H G Vogt; F Herrmann; M Freund; P Meusers; A Salama; H Heimpel
Journal:  N Engl J Med       Date:  1991-05-09       Impact factor: 91.245

5.  Circulating activated suppressor T lymphocytes in aplastic anemia.

Authors:  N C Zoumbos; P Gascón; J Y Djeu; S R Trost; N S Young
Journal:  N Engl J Med       Date:  1985-01-31       Impact factor: 91.245

6.  Phenotypic profile and functions of T cell receptor-gamma delta-bearing cells from patients with primary immunodeficiency syndrome.

Authors:  T Morio; M Nagasawa; S Nonoyama; H Okawa; J Yata
Journal:  J Immunol       Date:  1990-02-15       Impact factor: 5.422

7.  T cell-mediated inhibition of erythropoiesis in aplastic anaemia: the possible role of IFN-gamma and TNF-alpha.

Authors:  A Miura; K Endo; T Sugawara; J Kameoka; N Watanabe; K Meguro; O Fukuhara; I Sato; C Suzuki; K Yoshinaga
Journal:  Br J Haematol       Date:  1991-07       Impact factor: 6.998

8.  A subset of gamma delta lymphocytes is increased during HIV-1 infection.

Authors:  P De Paoli; D Gennari; P Martelli; G Basaglia; M Crovatto; S Battistin; G Santini
Journal:  Clin Exp Immunol       Date:  1991-02       Impact factor: 4.330

  8 in total
  3 in total

1.  Treatment of bone marrow failure syndrome with integrated traditional and Western medicine.

Authors:  Rou Ma
Journal:  Chin J Integr Med       Date:  2007-06       Impact factor: 1.978

2.  Clinical study on effect of Astragalus Injection and its immuno-regulation action in treating chronic aplastic anemia.

Authors:  Mao-sheng Wang; Jun Li; Hai-xia Di; Zhen-li Li; Shu-Lian Yang; Wei Hou; Jin-yu Yan; Xiao-min Zhao
Journal:  Chin J Integr Med       Date:  2007-06       Impact factor: 1.978

3.  Protective Effects of Chronic Intermittent Hypobaric Hypoxia Pretreatment against Aplastic Anemia through Improving the Adhesiveness and Stress of Mesenchymal Stem Cells in Rats.

Authors:  Jing Yang; Li Zhang; Handong Wang; Zan Guo; Yixian Liu; Yi Zhang; Chuan Wang; Quanhai Li
Journal:  Stem Cells Int       Date:  2017-07-16       Impact factor: 5.443

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.